What SCENESSE resolves to
SCENESSE is a product-specific afamelanotide 16 mg implant authorized in the United States and European Union for narrowly defined erythropoietic protoporphyria uses. Those authorizations do not transfer to seller-labelled Melanotan I research vials, compounded products, other presentations, indications, online sellers, or supply routes, and they do not establish local availability in every country.
- Evidence lane
- FDA-approved medicine
- Current record
- NDA 210797 · FDA-approved prescription drug
- Checked
- July 17, 2026